Co-Founder, President, CEO and Chairman of the Board AN2 Therapeutics
Eric Easom joined the DNDi Board in June 2026.
He is the Co-Founder, President, and CEO of AN2 Therapeutics and serves as Chair of its Board of Directors. With a passion for global health, Eric brings 35 years of experience across leading pharmaceutical and biotechnology companies, including Eli Lilly, McKesson, MedImmune (acquired by Astra Zeneca), and Anacor Pharmaceuticals (acquired by Pfizer).
Over his career, Eric has led efforts spanning drug discovery, development, business development, marketing, finance, and manufacturing, with a particular focus over the past 23 years on infectious diseases and neglected global health challenges. At Anacor, he built international collaborations that discovered more than a dozen potential therapies for malaria, tuberculosis, Chagas disease, and other devastating infections.
He currently serves on the Boards of the Chagas Disease Foundation and Resilient Biotics.
Get our latest news, personal stories, research articles, and job opportunities.
